Amgen and Allergan Submit European Application for Avastin® Biosimilar

EMA News

We recently reported that Amgen and Allergan had submitted an abbreviated Biologics License Application to the FDA for ABP 215, a biosimilar to Avastin® (bevacizumab).  Today, the companies announced that they have also submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for this product.

Stay tuned to Big Molecule Watch for further developments.

 

Download PDF

Comments are closed.